GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.